| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514774000 | Gelatin or derivative | 16 |
| 20080275140 | Process for Making a Low Molecular Weight Gelatine Hydrolysate and Gelatine Hydrolysate Compositions - The present invention provides a process to make a gelatine hydrolysate, a gelatine hydrolysate, and gelatine compositions including gelatine hydrolysates. More specifically, the invention provides gelatine compositions having a reduced tendency to cross-link and improved dissolution properties. | 11-06-2008 |
| 20090099268 | Anti-adhesion membrane - An object of the present invention is to provide an anti-adhesion membrane that has no toxicity to a living body, has flexibility allowing itself to fit an affected part as a hydrated gel, is uniformly crosslinked, and is immediately absorbed in a living body after maintaining its shape in the living body for a certain period of time. | 04-16-2009 |
| 20090182063 | RGD-ENRICHED GELATINE-LIKE PROTEINS WITH ENHANCED CELL BINDING - The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif. Preferably the RGD-enriched gelatines are prepared by recombinant technology, and have a sequence that is derived from a human gelatine or collagen amino acid sequence. The invention also relates to RGD-enriched gelatines that are used for attachment to integrins. In particular The RGD-enriched gelatines of the invention are suitable for coating a cell culture support for growing anchor-dependant cell types. Further, the RGD-enriched gelatines of the invention may find use in medical applications, in particular as a coating on implant or transplant material or as a component of drug delivery systems. | 07-16-2009 |
| 20100069512 | PROCESS FOR PREPARING AN OIL-IN-WATER EMULSION STABILISED WITH RECOMBINANT COLLAGEN-LIKE MATERIAL AND PRODUCTS PREPARED - The invention provides oil-in-water emulsions comprising recombinant collagen-like polymer in an amount sufficient to act as stabiliser of the emulsion. The polymer is especially a polypeptide which is free of helix structure, has an isoelectric point at least 0.5 pH units removed from the pH of the oil-in-water emulsion. Furthermore, bipolar recombinant collagen-like polymers are provided for use in oil-in-water emulsions. The bipolar polymers are polar at one end as a result of a relative abundance of polar amino acids, and apolar at the other end as a result of a relative abundance of apolar amino acids. | 03-18-2010 |
| 20100144902 | BIOCOMPATIBLE RAPID-GELATING HYDROGEL AND ASSOCIATED PREPARATION METHOD OF SPRAY - This invention discloses a preparation method for biocompatible rapid-gelating hydrogel. Wherein, hydrogel is formed by rapid chemical-crosslinking using the mixing and chemical-crosslinking reaction under specified conditions between several active compound components. The preparation method comprises the following steps: (1) The solution containing biocompatible thiolated macromolecular derivatives (component A) and biocompatible thiol reactive crosslinking agents (component B) mutually mix to form reactive mixture with specified crosslinking conditions; (2) the reactive mixture forms the hydrogel. The invention also discloses a preparation method for novel rapid-gelating hydrogel spray and an application in medical field. This invention has the advantages of good biocompatibility, no by-products, good stability, convenient use, small amount of raw materials used, suitable for many medical application, etc. | 06-10-2010 |
| 20110009497 | DRUG-CONTAINING COMPOSITION - It is an object of the present invention to provide a drug-containing composition which is capable of dissolving a poorly water-soluble drug, has low toxicity to the human body, and has high binding affinity with drugs. The present invention provides a composition which is composed of: (a) at least one poorly water-soluble compound; and (b) a carrier comprising a polymer (excluding plasma protein) having binding affinity with the poorly water-soluble compound. | 01-13-2011 |
| 20110071227 | RAPIDLY WETTING MATERIAL CONTAINING HYDROCOLLOID, METHOD FOR THE MANUFACTURE THEREOF AND USE THEREOF - The present invention relates to a method for the production of a quickly wettable material containing natural hydrocolloid in the form of a shaped body, in which a material containing natural hydrocolloid in the form of a shaped body is exposed to a plasma. | 03-24-2011 |
| 20110092605 | Encapsulation - Disclosed are encapsulating methods and encapsulated products. A payload material may be encapsulated within a wall material. The carrier material and payload material form a combination that is at least substantially solid at room temperature but that is sufficiently fluid at milling temperature to permit milling and subsequent encapsulation. The payload material may be, for instance, a bitter tasting material. In some embodiments, the microcapsules will serve a taste masking function. In other embodiments, the microcapsules may be used where a slow release of the payload material is desired. | 04-21-2011 |
| 20110224310 | CERAMIDE DISPERSION AND METHOD FOR PRODUCING SAME - The present invention provides a ceramide dispersion which includes (1) ceramide-containing particles which contain a ceramide, which are dispersed in an aqueous phase as an oil-phase component and which have a volume average particle diameter from 1 nm to 100 nm, (2) a fatty acid component which is at least one of a fatty acid and a fatty acid salt, (3) a polyhydric alcohol in an amount from 5 to 20 times larger than an amount of the ceramide and (4) a polysaccharide fatty acid ester; and in which the pH is from 6 to 8. | 09-15-2011 |
| 20130041044 | PHASE SEPARATED COMPOSITE - A composite is disclosed. The composite comprises a first conjugate of a polymer and a first phenol-containing moiety, and a second conjugate of a gelatin or collagen and a second phenol-containing moiety, wherein the polymer is selected so that the first conjugate is less cell-adhesive than the second conjugate, at least one of the first and second conjugates is crosslinked to form a matrix, and the composite comprises discrete regions that are rich in one of said first and second conjugates. A method of forming such composite is also disclosed. The method comprises mixing precursors for the first and second conjugates in a solution for forming said composite, and dispersing a catalyst in the solution to catalyze crosslinking of at least one of the first and second conjugates to form the matrix. The composite may be used to grow cells. | 02-14-2013 |
| 20130253074 | Implantation Material Comprising Biocompatible Polymer - Disclosed herein is a hyaluronic acid epoxide derivative film comprises a polymer containing a hydroxyl (—OH) terminal group. The film is prepared by allowing an epoxy crosslinker to react with a mixture of hyaluronic acid and a polymer containing a hydroxyl (—OH) terminal group and has improved physical strength, in vivo stability, flexibility, adhesiveness to biological tissue, and biocompatibility. | 09-26-2013 |
| 20140179803 | CONTINUOUS FLOW PRODUCTION OF GELATIN NANOPARTICLES - A continuous process for the preparation of gelatin based nanoparticles in a reactor having a process channel having a mixing element therein, the process having the following steps: A) feeding separately an aqueous gelatin solution at a first rate and a water-miscible organic solvent at a second rate to the process channel of the reactor to be mixed therein, to form a suspension of non-crosslinked gelatin based nanoparticles and B) crosslinking the non-crosslinked gelatin based nanoparticles, wherein the sum of the first rate and the second rate is chosen such that the reactor has a mixing efficiency as determined by the Villermaux/Dushman method of between 0.1 and 1.5 and the period from the time point at which the aqueous gelatin solution is fed to the reactor to the time point at which the mixture of the aqueous gelatin solution and the organic solvent contacts the mixing element is at most 15 seconds. | 06-26-2014 |
| 20140243429 | Enzyme-Degradable Polymer and Application Thereof - The present invention belongs to the biomedicine field and specifically concerns an enzyme-degradable polymer and the application thereof. To solve the problem of low sensitivity of the existing assay reagents, the present invention provides an enzyme-degradable polymer and the related application of the polymer. The present invention also provides hydrogels, nano-particles, fluorescent dye-labeled enzyme substrates and kits (packages) for detection or activity-analysis of biological enzymes based on the enzyme-degradable polymer. The formula of the enzyme-degradable polymer is P | 08-28-2014 |
| 20140316013 | CROSSLINKED GELATIN SUPPORT AND SUPPORT FOR CONTROLLED RELEASE OF PHYSIOLOGICALLY ACTIVE SUBSTANCE USING THE SAME - The present invention relates to a crosslinked gelatin support, in which a surface of a crosslinked gelatin is negatively charged and has a zeta potential in ethanol of from −3 to −50 mV, and a support for controlled release of a physiologically active substance, including: the crosslinked gelatin support; and a physiologically active substance adsorbed and retained on and/or inside the crosslinked gelatin support. | 10-23-2014 |
| 20140329915 | HYDROGEL ADAPTED FOR TREATMENT OF ACUTE DERMAL WOUNDS - The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods. | 11-06-2014 |
| 20150057370 | DRUG COMPOSITION AND SOFT CAPSULE DRUG SEALING THE DRUG COMPOSITION - A drug composition in a liquid form sealed within a soft capsule containing succinylated gelatin as a principal component thereof, the composition including (a) one kind of phenol derivative or a mixture of multiple kinds thereof and (b) a succinylated-gelatin insolubilizing agent; and a soft capsule drug including a capsule shell containing succinylated gelatin as a principal component thereof, the shell sealing therein a drug composition in a liquid form including (a) one kind of phenol derivative or a mixture of multiple kinds thereof; and (b) a succinylated-gelatin insolubilizing agent. | 02-26-2015 |
